Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucerastat + ERT in Fabry Disease
NCT02930655Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lucerastat in Fabry disease (FD) (2 arms), sponsored by Idorsia. Primary endpoints: Change from baseline in blood pressure at 12 weeks, Change from baseline in heart rate at 12 weeks and 5 more. Started Feb 2015; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT02930655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930655.